Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 184

1.

Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting.

Rdzak GM, Whitman LM, Inzucchi SE.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):217-222. doi: 10.1177/2042018818771433. Epub 2018 Apr 28.

2.

The role of mitogen-activated protein kinase-extracellular receptor kinase pathway in female fertility outcomes: a focus on pituitary gonadotropins regulation.

Kahnamouyi S, Nouri M, Farzadi L, Darabi M, Hosseini V, Mehdizadeh A.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):209-215. doi: 10.1177/2042018818772775. Epub 2018 May 7. Review.

3.

Incidence, mechanisms and impact outcome of hyperglycaemia in severe scorpion-envenomed patients.

Bahloul M, Turki O, Chaari A, Bouaziz M.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):199-208. doi: 10.1177/2042018818772779. Epub 2018 May 3. Review.

4.

The value of fast-acting insulin aspart compared with insulin aspart for patients with diabetes mellitus treated with bolus insulin from a UK health care system perspective.

Leelarathna L, Ashley D, Fidler C, Parekh W.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):187-197. doi: 10.1177/2042018818766816. Epub 2018 Apr 4.

5.

Improved outcomes for papillary thyroid microcarcinoma care: active surveillance and case volume.

Freni F, Galletti B, Galletti F, Dionigi G.

Ther Adv Endocrinol Metab. 2018 Jul;9(7):185-186. doi: 10.1177/2042018818773609. Epub 2018 May 4. No abstract available.

6.

Comparison of day 3 and day 5 thyroglobulin results after thyrogen injection in differentiated thyroid cancer patients.

Sager S, Hatipoglu E, Gunes B, Asa S, Uslu L, Sönmezoğlu K.

Ther Adv Endocrinol Metab. 2018 Jun;9(6):177-183. doi: 10.1177/2042018818770108. Epub 2018 Apr 17.

7.

Efficacy of gamification-based smartphone application for weight loss in overweight and obese adolescents: study protocol for a phase II randomized controlled trial.

Timpel P, Cesena FHY, da Silva Costa C, Soldatelli MD, Gois E Jr, Castrillon E, Díaz LJJ, Repetto GM, Hagos F, Castillo Yermenos RE, Pacheco-Barrios K, Musallam W, Braid Z, Khidir N, Romo Guardado M, Roepke RML.

Ther Adv Endocrinol Metab. 2018 Jun;9(6):167-176. doi: 10.1177/2042018818770938. Epub 2018 Apr 27.

8.

Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?

Biester T, Kordonouri O, Danne T.

Ther Adv Endocrinol Metab. 2018 May;9(5):157-166. doi: 10.1177/2042018818763247. Epub 2018 Mar 19. Review.

9.

The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes.

Inman TR, Plyushko E, Austin NP, Johnson JL.

Ther Adv Endocrinol Metab. 2018 May;9(5):151-155. doi: 10.1177/2042018818763698. Epub 2018 Apr 23. Review.

10.

9- and 13-HODE regulate fatty acid binding protein-4 in human macrophages, but does not involve HODE/GPR132 axis in PPAR-γ regulation of FABP4.

Vangaveti V, Shashidhar V, Collier F, Hodge J, Rush C, Malabu U, Baune B, Kennedy RL.

Ther Adv Endocrinol Metab. 2018 May;9(5):137-150. doi: 10.1177/2042018818759894. Epub 2018 Feb 27.

11.

Contemporary approaches to the management of polycystic ovary syndrome.

Pasquali R.

Ther Adv Endocrinol Metab. 2018 Apr;9(4):123-134. doi: 10.1177/2042018818756790. Epub 2018 Feb 7. Review.

12.

Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements.

Pearson SM, Trujillo JM.

Ther Adv Endocrinol Metab. 2018 Apr;9(4):113-121. doi: 10.1177/2042018818760962. Epub 2018 Mar 22.

13.

Awareness of diabetic retinopathy among people with diabetes in Jeddah, Saudi Arabia.

Alzahrani SH, Bakarman MA, Alqahtani SM, Alqahtani MS, Butt NS, Salawati EM, Alkatheri A, Malik AA, Saad K.

Ther Adv Endocrinol Metab. 2018 Apr;9(4):103-112. doi: 10.1177/2042018818758621. Epub 2018 Mar 4.

14.

Antidiabetic phytoconstituents and their mode of action on metabolic pathways.

Bharti SK, Krishnan S, Kumar A, Kumar A.

Ther Adv Endocrinol Metab. 2018 Mar;9(3):81-100. doi: 10.1177/2042018818755019. Epub 2018 Feb 12. Review.

15.

A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products.

Nuffer W, Guesnier A, Trujillo JM.

Ther Adv Endocrinol Metab. 2018 Mar;9(3):69-79. doi: 10.1177/2042018817752315. Epub 2018 Jan 19. Review.

16.

Hypersensitivity reactions to human insulin analogs in insulin-naïve patients: a systematic review.

Bzowyckyj AS, Stahnke AM.

Ther Adv Endocrinol Metab. 2018 Feb;9(2):53-65. doi: 10.1177/2042018817745484. Epub 2017 Dec 26. Review.

17.

Vascular affection in relation to oxidative DNA damage in metabolic syndrome.

Abd El Aziz R, Fawzy MW, Khalil N, Abdel Atty S, Sabra Z.

Ther Adv Endocrinol Metab. 2018 Feb;9(2):43-51. doi: 10.1177/2042018817750823. Epub 2018 Jan 22.

18.

Current best practice in the management of Turner syndrome.

Shankar RK, Backeljauw PF.

Ther Adv Endocrinol Metab. 2018 Jan;9(1):33-40. doi: 10.1177/2042018817746291. Epub 2017 Dec 18. Review.

19.

Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always.

Raghav A, Khan ZA, Labala RK, Ahmad J, Noor S, Mishra BK.

Ther Adv Endocrinol Metab. 2018 Jan;9(1):29-31. doi: 10.1177/2042018817744513. Epub 2017 Dec 12. Review.

20.

Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety.

Mills EP, Brown KPD, Smith JD, Vang PW, Trotta K.

Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7. Review.

Supplemental Content

Loading ...
Support Center